PSMB5
Proteasome subunit beta type-5
As of the edition of 20 October 2026, PSMB5 (proteasome subunit beta type-5, UniProt P28074) has 6 drugs tested at it and 13 companies on the list, 2 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P28074
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 158
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Urinary and reproductive; Lungs and airways; Nutrition and metabolism; Pregnancy and women's health
- Registered trials of its drugs
- 1,227
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Went quiet | 1 |
| Status not established | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Bortezomib | Marketed | Phase 4 | none listed |
| Carfilzomib | Marketed | Phase 4 | Ends 2028 |
| Ixazomib | Marketed | Phase 4 | none listed |
| Ixazomib citrate | Marketed | Phase 3 | Ends 2029 |
| Delanzomib | Went quiet | Phase 2 | none listed |
| TQB3602 | Status not established | Phase 1 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 3 |
| Engaged | 6 |
| Undetermined | 2 |
| Total on the list | 13 |
| Company | Route |
|---|---|
| Amgen | Route B |
| Teva | Route A |
| Johnson & Johnson | Route B |
The other 10 companies at PSMB5
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at PSMB5, ranked, with the facts behind eachRequest access. Nothing is shown until you do.